Johnson & Johnson Reports registry Data for Ciltacabtagene autoleucel in Spinal muscular atrophy

Johnson & Johnson today announced registry results for ciltacabtagene autoleucel in patients with spinal muscular atrophy. The study demonstrated that ciltacabtagene autoleucel demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of spinal muscular atrophy and support the continued development of ciltacabtagene autoleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.